Skip to Main Content

As part of an ongoing quest to reform the pharmaceutical industry, the Federal Trade Commission reached a sweeping settlement with Teva Pharmaceuticals (TEVA), one of the largest generic suppliers, over so-called pay-to-delay deals that the agency says greatly increase consumer drug costs.

The agreement resolves three pending cases against Teva and significantly expands a settlement reached four years ago in another case that at the time was considered a landmark. In that deal, Teva paid $1.2 billion to resolve claims a subsidiary violated antitrust law, the first time the FTC recovered money on behalf of consumers and others who pay for medicines, such as pharmacies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.